Now turning to 2024 guidance on slide 13, where we highlight the items driving our 2024 revenue guidance range. As Kevin mentioned, we've tightened our revenue range and raised the midpoint by $50,000,000 representing 1.8% to 2.6% nominal growth year on year, which equates to 3.1% to 3.8% on a constant currency basis. For LOE, we lowered our range from $70,000,000 to $90,000,000 to $40,000,000 to $50,000,000 which reflects slower uptake for generics for Atazette. Moving to the right, we lowered the range on VBP impact from $30,000,000 to $50,000,000 to $15,000,000 to $25,000,000 which similarly reflects a slight delay in realizing the full revenue impact of round 8 for Remeron and Hizar. We've been doing a bit better on price year to date, so we lowered our view of pricing impact from $180,000,000 to $200,000,000 to $145,000,000 to $155,000,000 representing an approximate 2.5 percentage point headwind versus prior year, which is in line with our longer term expectations from price across our entire business.